Former Merck and NASA Veterans Join SpaceMD Advisory Board

Redwire Corporation (NYSE: RDW) announced the appointment of Paul Reichert, a former senior executive at Merck (NYSE: MRK), and Niki Werkheiser, a former NASA director, to strategic advisory roles at SpaceMD (Space Microgravity Development), its venture focused on pharmaceutical development in microgravity.

The Appointments

The appointments come as the space pharma industry gains momentum, with companies seeking to leverage microgravity conditions to improve drug crystallization and formulation.

• Paul Reichert: Former Senior Vice President at Merck, where he led the development of blockbuster drugs including Keytruda. He brings extensive R&D expertise.
• Niki Werkheiser: Served over 20 years at NASA, most recently as Director of the ISS Research and Development Program. She facilitated numerous scientific experiments in space.

Context

SpaceMD was founded in 2025 as a Redwire subsidiary to explore the potential of manufacturing pharmaceuticals in space. Previous research has shown that protein crystallization in microgravity can yield more pure structures, enhancing drug efficacy.

What This Means for Investors

The appointments underscore Redwire's commitment to expanding its space pharma business, a nascent market that could see significant growth as interest in space-based manufacturing increases. For Merck investors, Reichert's move to SpaceMD may signal potential future collaboration between the two companies.